GoodRx upgraded to Buy at DA Davidson on increased confidence

DA Davidson analyst Robert Simmons upgraded GoodRx to Buy from Neutral with a price target of $9.50, up from $5.50, after GoodRx posted what the firm calls a “solid” Q2 report. While GoodRx provided “mixed” guidance as management evolves the business and works through short-term headwinds, the firm has increased confidence in the company’s ability to achieve revised numbers as GoodRx continues to improve predictability and drive focus and efficiency, the analyst tells investors.